Premium
Everolimus‐associated perianal ulcers in an eight‐month‐old heart transplant recipient
Author(s) -
Spehl Marco S.,
Fleck Thilo,
Schauer Franziska,
Meiss Frank,
Stiller Brigitte
Publication year - 2018
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13072
Subject(s) - medicine , everolimus , discontinuation , discovery and development of mtor inhibitors , adverse effect , sirolimus , heart transplantation , intensive care medicine , transplantation , pi3k/akt/mtor pathway , surgery , pediatrics , apoptosis , biochemistry , chemistry
mTOR inhibitors have a wide spectrum of therapeutic applications in adults and children. Little is known, however, about serious adverse effects in children undergoing mTOR inhibitor therapy. Oral ulcers are common and sometimes severe, but no other gastrointestinal involvement has been reported so far. Here we present a case of everolimus‐associated perianal ulcers in an eight‐month‐old infant, 3 months after heart transplantation, which necessitated the drug's discontinuation. In a thorough series of diagnostic tests, we identified no other cause for the progressive perianal ulceration. The recognition and appropriate management of mTOR inhibitors' adverse effects in pediatric patients are essential and remain challenging.